These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22248133)

  • 61. Othello syndrome and chronic dopaminergic treatment in patients with Parkinson's disease.
    Kataoka H; Kiriyama T; Eura N; Sawa N; Ueno S
    Parkinsonism Relat Disord; 2014 Mar; 20(3):337-9. PubMed ID: 24054315
    [No Abstract]   [Full Text] [Related]  

  • 62. Dopamine dysregulation syndrome in Parkinson's disease.
    Evans AH; Lees AJ
    Curr Opin Neurol; 2004 Aug; 17(4):393-8. PubMed ID: 15247533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pathological gambling in Parkinson's disease.
    O'Sullivan SS; Lees AJ
    Lancet Neurol; 2007 May; 6(5):384-6. PubMed ID: 17434085
    [No Abstract]   [Full Text] [Related]  

  • 64. Substance of abuse and movement disorders: complex interactions and comorbidities.
    Deik A; Saunders-Pullman R; Luciano MS
    Curr Drug Abuse Rev; 2012 Sep; 5(3):243-53. PubMed ID: 23030352
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
    Kuno S; Mizuta E; Yamasaki S
    Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy.
    Poletti M; Frosini D; Pagni C; Baldacci F; Lucetti C; Del Dotto P; Ceravolo R; Bonuccelli U
    Neurol Sci; 2014 Oct; 35(10):1603-5. PubMed ID: 25012755
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel insights in pharmacogenetics of drug response in Parkinson's disease.
    Arbouw ME; Guchelaar HJ; Egberts TC
    Pharmacogenomics; 2010 Feb; 11(2):127-9. PubMed ID: 20136351
    [No Abstract]   [Full Text] [Related]  

  • 68. Disease-modifying strategies and challenges in PD: interactive breakout sessions.
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S56-63. PubMed ID: 14504381
    [No Abstract]   [Full Text] [Related]  

  • 69. Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia.
    Schmidt WJ; Beninger RJ
    Neurotox Res; 2006 Oct; 10(2):161-6. PubMed ID: 17062377
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impulsive-compulsive behaviours in Parkinson's disease--prevention is better than cure.
    Ryan SA; O'Sullivan SS
    Ir Med J; 2013 Jun; 106(6):162. PubMed ID: 23909147
    [No Abstract]   [Full Text] [Related]  

  • 71. Preface: Malignant syndrome in Parkinson's disease.
    Narabayashi H; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S1. PubMed ID: 12735908
    [No Abstract]   [Full Text] [Related]  

  • 72. Prescribing in Parkinson's disease: a story of hope and adverse events.
    Morrish P
    Pract Neurol; 2012 Oct; 12(5):335-40. PubMed ID: 22976066
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [DOPA-responsive dystonia (Segawa's disease)].
    Bobylova MIu; Mikhaĭlova SB; Grinio LP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):73-6. PubMed ID: 19817010
    [No Abstract]   [Full Text] [Related]  

  • 74. [Complications of therapy of advanced stages Parkinson's disease and possible approaches to their correction].
    Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(4):52-6. PubMed ID: 12001669
    [No Abstract]   [Full Text] [Related]  

  • 75. "Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?" Letter to the editor reply.
    Coon EA; Laughlin RS
    J Headache Pain; 2012 Nov; 13(8):687. PubMed ID: 23054065
    [No Abstract]   [Full Text] [Related]  

  • 76. Hyper-dopaminergic ballismus and respiratory dyskinesia treated with intravenous haloperidol.
    McLay SV; MacDonald SP
    Emerg Med Australas; 2014 Dec; 26(6):647-8. PubMed ID: 25312487
    [No Abstract]   [Full Text] [Related]  

  • 77. Aberrant sexual behaviours in Parkinson's disease during dopaminergic treatment.
    Cannas A; Solla P; Floris GL; Serra G; Tacconi P; Marrosu MG
    J Neurol; 2007 Jan; 254(1):110-2. PubMed ID: 17278043
    [No Abstract]   [Full Text] [Related]  

  • 78. Risk prediction and treatment monitoring are crucial for prevention and management of compulsive dopamine use in Parkinson's disease.
    van den Heuvel OA
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):244. PubMed ID: 23674573
    [No Abstract]   [Full Text] [Related]  

  • 79. Treatment of methamphetamine dependence.
    Mendelson J; Rawson R; Newton T; Galloway G; de Wit H; Dewey SL; Hart CL; Epstein DH
    Mayo Clin Proc; 2008 Mar; 83(3):369-70; author reply 370-1. PubMed ID: 18316008
    [No Abstract]   [Full Text] [Related]  

  • 80. Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy.
    Nishiyama K; Momose T; Sugishita M; Sakuta M
    J Neurol Sci; 1995 Sep; 132(1):89-92. PubMed ID: 8523038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.